Near real-time surveillance for Guillain-Barré syndrome after influenza vaccination among the Medicare population, 2010/11 to 2013/14

Vaccine

Volumn 35, Issue 22, 2017, Pages 2986-2992

  Sandhu, Sukhminder K ^a   Hua, Wei ^a   MaCurdy, Thomas E ^b,c   Franks, Riley L ^c   Avagyan, Armen ^c   Kelman, Jeffrey ^d   Worrall, Christopher M ^d   Ball, Robert ^a   Nguyen, Michael ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Acumen LLC   (United States)

^d Centers for Medicare and Medicaid Services   (United States)

Author keywords

Flu; Guillain Barr syndrome; Immunization; Influenza; Vaccine

Indexed keywords

INFLUENZA VACCINE;

AGED; ARTICLE; DISEASE SURVEILLANCE; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; ICD-9; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MEDICARE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; SEASONAL INFLUENZA; SENSITIVITY ANALYSIS; SEQUENTIAL ANALYSIS; UPDATING SEQUENTIAL PROBABILITY RATIO TEST; COMPUTER SYSTEM; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH SURVEY; PROCEDURES; RISK ASSESSMENT; UNITED STATES; VACCINATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CENTERS FOR MEDICARE AND MEDICAID SERVICES (U.S.); COMPUTER SYSTEMS; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; INFLUENZA VACCINES; MALE; MEDICARE; POPULATION SURVEILLANCE; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VACCINATION;

EID: 85018859469     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.03.087     Document Type: Article

References (19)

1. [1] Burwen, D.R., et al. Evaluating adverse events after vaccination in the Medicare population. Pharmacoepidemiol Drug Saf 16:7 (2007), 753–761.
2. [2] Burwen, D.R., et al. Evaluation of Guillain-Barre syndrome among recipients of influenza vaccine in 2000 and 2001. Am J Prev Med 39:4 (2010), 296–304.
3. [3] Hartzema, A.G., et al. Utilizing Medicare claims data for real-time drug safety evaluations:is it feasible?. Pharmacoepidemiol Drug Saf 20:7 (2011), 684–688.
4. [4] Kulldorff, M., et al. A maximized sequential probability ratio test for drug and vaccine safety surveillance. Sequential Anal 30:1 (2011), 58–78.
5. [5] Franks, R.S.S., Avagyan, A., Lu, Y., Hong, H., Garcia, B., Worrall, C., et al. Robustness properties of a sequential test for vaccine safety in the presence of misspecification. Statist Anal Data Min 7:5 (2014), 368–375.
6. [6] Langmuir, A.D., et al. An epidemiologic and clinical evaluation of Guillain-Barre syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol 119:6 (1984), 841–879.
7. [7] Safranek, T.J., et al. Reassessment of the association between Guillain-Barre syndrome and receipt of swine influenza vaccine in 1976–1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol 133:9 (1991), 940–951.
8. [8] Schonberger, L.B., et al. Guillain-Barre syndrome following vaccination in the national influenza immunization program, United States, 1976–1977. Am J Epidemiol 110:2 (1979), 105–123.
9. [9] Polakowski, L.L., et al. Chart-confirmed Guillain-Barre syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009–2010. Am J Epidemiol 178:6 (2013), 962–973.
10. [10] Greene, S.K., et al. Guillain-Barre syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: a case-centered analysis in the Vaccine Safety Datalink, 2009–2011. PLoS ONE, 8(6), 2013, e67185.
11. [11] https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/MM7234.pdf.
12. [12] Centers for Disease, C. and Prevention, Influenza activity–United States, 2012–13 season and composition of the 2013–14 influenza vaccine. MMWR Morb Mortal Wkly Rep 62:23 (2013), 473–479.
13. [13] SK S. https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0ahUKEwioqPOFzL3QAhULwmMKHd0BDNoQFggbMAA&url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FAdvisoryCommittees%2FCommitteesMeetingMaterials%2FBloodVaccinesandOtherBiologics%2FVaccinesandRelatedBiologicalProductsAdvisoryCommittee%2FUCM284606.ppt&usg=AFQjCNE5Mu44wwJH4jNuKgfN5Tg7sArpAg&sig2=_LH1GX-u-ReuSLkmxsMMYw&bvm=bv.139782543,d.amc; 2011.
14. [14] Tam, C.C., et al. Guillain-Barre syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database. PLoS ONE, 2(4), 2007, e344.
15. [15] Vellozzi, C., Iqbal, S., Broder, K., Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis 58:8 (2014), 1149–1155.
16. [16] Centers for Disease, C. and Prevention, Update: influenza activity–United States, 2010–11 season, and composition of the 2011–12 influenza vaccine. MMWR Morb Mortal Wkly Rep 60:21 (2011), 705–712.
17. [17] Centers for Disease, C. and Prevention, Update: influenza activity - United States, 2011–12 season and composition of the 2012–13 influenza vaccine. MMWR Morb Mortal Wkly Rep 61:22 (2012), 414–420.
18. [18] Burwen, D.R., et al. Surveillance for Guillain-Barre syndrome after influenza vaccination among the Medicare population, 2009–2010. Am J Public Health 102:10 (2012), 1921–1927.
19. [19] Yih, W.K., et al. Prospective influenza vaccine safety surveillance using fresh data in the sentinel system. Pharmacoepidemiol Drug Saf 25:5 (2016), 481–492.